Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Edwards Lifesciences Corporation
  6. News
  7. Summary
    EW   US28176E1082

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tranche Update on Edwards Lifesciences Corporation (NYSE:EW)'s Equity Buyback Plan announced on May 5, 2021.

04/28/2022 | 04:08pm EDT
share with twitter
share with LinkedIn
share with facebook

From January 1, 2022 to March 31, 2022, the company has repurchased 2,529,839 shares, representing 0.41% for $277.59 million. With this, the company has completed the repurchase of 2,529,839 shares, representing 0.41% for $277.59 million under the buyback announced on May 5, 2021.


© S&P Capital IQ 2022
All news about EDWARDS LIFESCIENCES CORPORATION
06/15INSIDER SELL : Edwards Lifesciences
MT
06/09Corvia Medical, Inc. announced that it has received $54 million in funding from Accelme..
CI
06/09Corvia Medical, Inc. announced that it has received $54 million funding from General Ca..
CI
06/02TRANSCRIPT : Edwards Lifesciences Corporation Presents at Bernstein 38th Annual Strategic ..
CI
05/23Edwards lifesciences to present at the bernstein 38th annual strategic decisions confer..
PR
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Bu..
MT
05/16Edwards announces key events for europcr 2022
PR
05/11INSIDER SELL : Edwards Lifesciences
MT
05/04EDWARDS LIFESCIENCES CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 737 M - -
Net income 2022 1 573 M - -
Net cash 2022 1 336 M - -
P/E ratio 2022 39,0x
Yield 2022 -
Capitalization 60 552 M 60 552 M -
EV / Sales 2022 10,3x
EV / Sales 2023 9,05x
Nbr of Employees 15 700
Free-Float 95,9%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 97,39 $
Average target price 124,33 $
Spread / Average Target 27,7%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-24.82%60 552
THERMO FISHER SCIENTIFIC-18.58%214 627
DANAHER CORPORATION-21.57%184 737
INTUITIVE SURGICAL, INC.-42.64%73 981
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.-18.06%56 317
SIEMENS HEALTHINEERS AG-26.88%56 147